Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC By Ogkologos - January 30, 2026 2 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASCENT-04/KEYNOTE-D19 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing MOST POPULAR Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible... November 18, 2024 “Chameleon-Like” Breast Cancer Cells Disguised as Neurons Can Lead to Brain... June 8, 2021 COVID-19: “It could take months to build research up again” July 1, 2020 2021 ASCO Annual Meeting: New Treatments and Research Advances in Esophageal... June 3, 2021 Load more HOT NEWS Nivolumab: Μία σημαντική θεραπευτική επιλογή 7 images that defined cancer policy in 2022 Adding Autologous Stem-Cell Transplantation to Triplet Treatment, Followed by Lenalidomide Maintenance... EMA Recommends Granting a Conditional Marketing Authorisation for Sotorasib
